Compare LPL & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPL | IOVA |
|---|---|---|
| Founded | 1985 | 2007 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 968.6M |
| IPO Year | 2004 | N/A |
| Metric | LPL | IOVA |
|---|---|---|
| Price | $4.16 | $2.56 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $10.45 |
| AVG Volume (30 Days) | 340.3K | ★ 11.3M |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,822,679,522.00 | $250,425,000.00 |
| Revenue This Year | N/A | $60.94 |
| Revenue Next Year | $0.81 | $60.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 1.01 | ★ 175.62 |
| 52 Week Low | $2.43 | $1.64 |
| 52 Week High | $5.67 | $8.15 |
| Indicator | LPL | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 58.51 |
| Support Level | $4.09 | $2.08 |
| Resistance Level | $4.19 | $2.60 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 13.03 | 77.88 |
LG Display Co Ltd is a South Korea-based company that is principally engaged in developing, manufacturing, and selling TFT-LCD and OLED display panels. The company's products consist of panels for notebook computers, monitors, televisions, smartphones, tablets, and others. The company conducts direct sales through overseas subsidiaries in several countries, including the United States, Germany, Japan, Taiwan, China, and Singapore. These subsidiaries conduct sales activities and offer technical support to clients. The company generates the majority of its revenue from overseas markets, with the rest from South Korea.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.